News | July 25, 2013

Merck Submits New Drug Application for Antithrombotic Vorapaxar

Vorapaxar is for the secondary prevention of cardiovascular events in patients who had a history of heart attack


July 25, 2013 — Merck announced that the New Drug Application (NDA) for its investigational anti-thrombotic medicine, vorapaxar, has been accepted for standard review by the U.S. Food and Drug Administration (FDA).

Merck is seeking FDA approval of vorapaxar for the secondary prevention of cardiovascular events in patients with a history of heart attack and no history of stroke or transient ischemic attack (TIA).

For more information: www.merck.com


Additional Content

News | Pharmaceuticals

July 16, 2026 — Merck has received U.S. Food and Drug Administration (FDA) approval for Lipfendra (enlicitide) tablets ...

Home July 16, 2026
Home
News | Pharmaceuticals

Jan. 27, 2026 — Cytokinetics, Inc. has announced that Myqorzo (aficamten) is now available for prescription in 5 mg, 10 ...

Home January 28, 2026
Home
News | Pharmaceuticals

Nov. 19, 2025 — Promising results from a pivotal Phase 3 clinical trial of an investigational heart-attack drug were ...

Home November 19, 2025
Home
News | Pharmaceuticals

Sept. 25, 2025 — Kardigan has introduced the three late-stage clinical programs leading its robust pipeline, each ...

Home September 25, 2025
Home
News | Pharmaceuticals

Sept. 23, 2025 — CeleCor Therapeutics’ multinational Phase 3 clinical trial of its investigational heart-attack drug ...

Home September 23, 2025
Home
Subscribe Now